CAP satellite symposiums are live educational programs with CME funded through a grant by an exhibitor and independently organized by a third party.
Monday, October 22
Personalized Medicine in Oncology enabled by Next-Generation Sequencing
Time: 6:30 pm
This 1.5 hours satellite symposium will provide the learner with an introduction to Genomics and a quick overview of Next-Generation Sequencing (NGS) to better understand the technology that allows sequencing of DNA/RNA much more quickly. The presentation will include specific oncology applications including tumor mutational burden, tumor profiling as it applies to colorectal cancer, and microsatellite instability (MSI), the condition of genetic predisposition to mutation that results from impaired DNA mismatch repair (MMR). The presence of MSI represents that MMR is not functioning normally. It will conclude with a review of the human microbiome, which covers all microbes genes, and immunotherapy.
- Define how genomics and knowledge of DNA has impacted patient care
- Review the broad range of applications and experiments that can be performed with NGS
- Discuss how microsatellite instability and tumor mutational burden test results can help with immunotherapy decisions
CME Accreditation and Designation Statements
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This satellite symposium is supported through an educational grant from ILLUMINA.
Tuesday, October 23
Assessing RET-Altered Tumors: An Increasingly Important Target For Personalized Oncology Care
Time: 6:30 pm
It is well-known that point mutations and gene rearrangements/fusions in RET can drive oncogenesis in various solid tumors. However, exciting new data have emerged that suggest selective RET inhibitors have promising anti-tumor activity in patients with these alterations. A critical component of personalized cancer care requires that pathologists understand these new data and, more importantly, are equipped to detect RET alterations so that appropriate patients are offered treatment and enrollment on clinical trials that can improve their clinical outcomes.
This interactive symposium will serve as an ideal forum for attendees to directly engage with and learn from leading pathology experts. Symposium attendees will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and contribute to the symposium cases. This program is designed to provide pathologists insights on the application of the latest clinical data on selective RET inhibitors along with practical guidance to facilitate the detection of RET alterations.
- Discuss the concept of “oncogene addiction” and the dependency on a single activated kinase for proliferation and survival in RET fusion cancers and RET-mutant MTC
- Describe the rationale for reflexive testing of RET in lung and thyroid tumors
- Select evidence-based testing strategies to detect RET fusions and mutations
- Tailor patient treatment protocols using RET inhibitors as part of a multidisciplinary team collaboration
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Loxo Oncology.